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Abstract
Purpose To compare the effects of two stretching devices, the TheraBite® Jaw Motion Rehabilitation System™ and the
Dynasplint Trismus System®, on maximal mouth opening in head and neck cancer patients.
Methods Patients were randomly assigned to one of two exercise groups: the TheraBite® Jaw Motion Rehabilitation System™
group or the Dynasplint Trismus System® group. Patients performed stretching exercises for 3 months. During the three study
visits, maximal mouth opening was measured and the patients completed questionnaires on mandibular function and quality of life.
Results In our study population (n = 27), five patients did not start the exercise protocol, eight patients discontinued exercises,
and two patients were lost to follow-up. No significant differences regarding the change in mouth opening between the two
devices were found. Patients had an increase in MMO of 3.0 mm (IQR − 2.0; 4.0) using the TheraBite® Jaw Motion
Rehabilitation System™ and 1.5 mm (IQR 1.0; 3.0) using the Dynasplint Trismus System®. Exercising with either stretching
device was challenging for the patients due to the intensive exercise protocol, pain during the exercises, fitting problems with the
stretching device, and overall deterioration of their medical condition.
Conclusions The effects of the two stretching devices did not differ significantly in our study population. The factors described,
influencing the progression of stretching exercises, need to be taken into account when prescribing a similar stretching regimen
for trismus in head and neck cancer patients.
Trial registration NTR - Dutch Trial Register number: 5589
Keywords Head and neck neoplasms .Mouth neoplasms . Trismus . Quality of life . Rehabilitation . Exercise therapy
Introduction
To treat trismus in head and neck cancer patients, a variety of
exercise therapies are prescribed [1]. Exercise therapy with
stretching devices such as the TheraBite® Jaw Motion
Rehabilitation System™ (TheraBite) and the Dynasplint
Trismus System® (DTS) have been reported to increase
mouth opening up to 14 mm [2–4]. However, the effects of
these two devices have not been compared side-by-side. In a
randomized controlled trial, we compared the effects of the
TheraBite and the DTS on mouth opening in head and neck
cancer patients with trismus.
Materials and methods
Patients were eligible if they were at least 18 years old and if
they were treated for head and neck cancer and had a maximal
mouth opening (MMO) of 35 mm or less. Based on a sample
size calculation, 24 patients per group were needed. To com-
pensate for drop-outs, we aimed to include 30 patients per
group. The patients were randomized on the basis of two
strata, with blocks of four with an allocation ratio of one.
One stratum included patients who received cancer treatment
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less than 36 months ago, and the other included patients who
received cancer treatment 36 months ago or longer.
During the first visit (T1), the stretching device and a diary
were provided. During all three study visits, patients filled in
questionnaires regarding mandibular function and quality of
life and their MMO was measured. An interview was held
about patients’ experiences with the stretching devices and
the exercise protocol, during the last two visits (T2, T3).
More details can be found in Supplementary Material Text 1.
Results
In total, 166 patients were assessed for eligibility, of which 86
did not meet the inclusion criteria, 35 declined to participate,
and 18 did not participate due to other reasons. Patients de-
clined to participate because they thought the protocol was too
intensive or because they had no treatment need. Other rea-
sons for non-participation were overall poor health, old age (≥
80 years), or because using the stretching device was not pos-
sible due to previous extensive oncological treatment (such as
hemi-mandibulectomy or large cheek resections). Of the 27
patients who were eventually enrolled in the study, five pa-
tients did not start the exercise program due to reconsideration
of the exercise program (n = 2; too intensive, too much comor-
bidity), occurrence or suspicion of new tumor (n = 2), and
because the use of a stretching device was not possible (n =
1; high sensitivity of the lower jaw). Of the 22 patients who
started the protocol, eight discontinued exercises due to de-
pression (n = 1), painful mouth/neck (n = 3), recurrent tumor
(n = 1), overly intensive protocol (n = 2), and the use of
stretching device was not possible (n = 1) (MMO of 7 mm).
Two patients were lost to follow-up.
Eleven adverse events occurred (Supplementary Material
Text 2). Four serious adverse events were reported, but were
unrelated to the stretching device (metastasis (n = 1), recurrent
tumor growth (n = 2), and new primary tumor (n = 1).
The study was stopped prematurely due to the low inclu-
sion rate and high attrition rate.
No significant differences regarding the change in mouth
opening between the two stretching devices were found.
Patients who exercised with the TheraBite gained 3.0 mm
(IQR − 2.0; 4.0) and those who exercised with the DTS gained
1.5 mm (1.0; 3.0) (p = 0.628). Patients who started exercises
36 months or less after tumor treatment gained 2.5 mm (IQR
1.0; 3.0) and those who started more than 36 months after
tumor treatment 2.0 mm (IQR − 2.0; 4.0) (p = 0.936). One
patient recovered from trismus. This patient, who received
the TheraBite, had an MMO of 33 mm on T1 and 38 mm on
T2 and T3. Additional data can be found in Supplementary
Material Tables 1–3.
During the interview, five patients stated that they experi-
enced a gain in mouth opening immediately after exercises,
but it declined soon thereafter. Two patients reported a gain in
mouth opening during the first weeks (approximately
4 weeks), but no further gain thereafter. Three patients report-
ed no effect even though they complied with the protocol
regimen. One patient reported more saliva flow in the front
part of the mouth, four patients reported improved suppleness
of the mouth (which led to improvements in speaking and
eating), one patient reported improved smell and taste, but
was in doubt whether it was related to the stretching exercises.
Two patients who received the TheraBite reported difficulties
with using the device due to insufficient grip as the plates
became slippery and due to hampered movement as the rota-
tion angle of the lower plate and the lower jaw were not the
same. One patient who received the DTS reported difficulty
applying enough force, as the upper denture tilted when force
was applied.
Discussion
No significant effects were found between the stretching de-
vices regarding mouth opening. Other studies reported greater
effects after stretching; 5.4 mm (SD 5.7) using the TheraBite
[5] or 6.2 mm (SD 3.4) using the DTS [6]. Both studies were
retrospective in the design, which might have led to selection
bias and an overestimation of the effect. Additionally, both of
these studies had a higher frequency of follow-up appoint-
ments at shorter intervals, during which patients were in-
formed, guided, and motivated, which might have led to im-
proved compliance and better execution of exercises [5, 6].
Our high attrition rate (56%) and subsequently our small
sample size might have been too small to detect the effects of
the two stretching devices. High attrition rates are common in
similar studies, ranging from 11 to 42% [6–11].Most common
reasons for drop-out are either related to other patient factors,
such as mortality [6–9, 12], tumor progression (recurrent tu-
mor or metastasis) [7, 8, 12], or lack need for treatment [7] or
are related to stretching problems, such as pain during exer-
cises [8, 10, 11], no perceived improvement [6], and fitting
issues of stretching device [7, 10]. In future studies these fac-
tors influencing the progression of the stretching protocol
need to be taken into account.
Conclusion
No differences in effects between the TheraBite and DTSwere
found in our study population. High attrition rates and
stretching problems are common when prescribing an inten-
sive stretching protocol on head and neck cancer patients.
Data The corresponding author has full control of all primary
data. Primary data is available on request.
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